Thymosin Beta-4 (Full-Length 43-AA) vs. TB-500: Complete Protocol Guide
Also known as: Tβ4 (43-AA), Timbetasin, RGN-259, Thymosin Beta-4 vs. TB-500 (Ac-LKKTETQ)
Studied in published research — not a medical recommendation. Primary protocol (Full-Length 43-AA Thymosin Beta-4 Daily Tissue & Anti-Fibrotic Protocol): 500 mcg – 1,500 mcg (0.5–1.5 mg), Once daily.
Once daily
Research-reported range (no primary dosing study). Daily dosing leverages the shorter plasma half-life of intact 43-AA Tβ4 and maintains steady Ac-SDKP anti-fibrotic cleavage
Subcutaneous injection
Human clinical trials or FDA-approved formulation exists
No verified human half-life on file for this compound
A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.
All U-100: 100 units = 1 mL. 10 doses in the vial at the low end (3 doses at the high end).
Save Thymosin Beta-4 (Full-Length 43-AA) to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.
At a Glance · 2026 FDA / 503A / WADA / Evidence Profile
What is a Peptide?
A short chain of amino acids (2-50) linked by peptide bonds. Smaller than proteins. Your body produces thousands of peptides naturally as signaling molecules that regulate everything from appetite to healing. Therapeutic peptides mimic or enhance these natural signals.
Bottom Line Up Front
Thymosin Beta-4 (Full-Length 43-AA, MW 4,963 Da, Timbetasin / RGN-259) is the complete endogenous regenerative polypeptide containing both the N-terminal Ac-SDKP anti-fibrotic tetrapeptide (residues 1–4) and the central G-actin binding domain (residues 17–23, LKKTETQ), whereas true TB-500 (MW 889 Da) isolates only the 7-AA Ac-LKKTETQ fragment.
Corneal/dermal wound repair (Phase 3 RGN-259), angiogenesis, and Ac-SDKP anti-fibrotic organ protection
Unverified vendor vials that conflate 43-AA Tβ4 (4,963 Da) with 7-AA TB-500 (889 Da) without LC-MS mass spec verification
RGN-259 / Timbetasin (RegeneRx — Phase 3 Ophthalmic/Dermal)
3 (0 human)
EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. Thymosin Beta-4 (Full-Length 43-AA) is not FDA approved for human use (unless specified above). This information does not constitute medical advice.
Overview
First isolated from thymus extract by Allan Goldstein and colleagues, Thymosin Beta-4 (TMSB4X) is the primary intracellular G-actin sequestering peptide in mammalian tissue. When tissue injury occurs, platelets and macrophages release full-length 43-AA Tβ4 into the extracellular matrix. Full-length Tβ4 drives repair through multiple distinct domains: residues 1–4 (Ac-SDKP) are cleaved by prolyl oligopeptidase to exert potent anti-fibrotic, anti-inflammatory, and cardioprotective effects; residues 17–23 (LKKTETQ, the sequence sold as true TB-500) bind actin and promote endothelial/keratinocyte migration and angiogenesis; and the C-terminal region supports hair follicle stem cell and dermal matrix remodeling.
Mechanisms of Action
- Residues 17–23 (LKKTETQ) sequester monomeric G-actin and stimulate endothelial, myoblast, and keratinocyte cell migration and angiogenesis
- Residues 1–4 (N-terminal Ac-SDKP tetrapeptide, present ONLY in full-length 43-AA Tβ4) inhibit TGF-β/Smad3 organ fibrosis and suppress NF-κB macrophage inflammation
- Up-regulates VEGF, laminin-5, and matrix metalloproteinase balance for scarless dermal, corneal, and tendon remodeling
- Activates epicardial progenitor cells and hair follicle bulge stem cells
Common Ratios, Vial Formats & Dosing Breakdown
Researchers use different ratios depending on whether they reconstitute a pre-mixed vial or draw from separate single-compound vials.
Full-Length Thymosin Beta-4 (43-AA, 4,963 Da) vs. TB-500 Fragment (7-AA Ac-LKKTETQ, 889 Da)
5 mg or 10 mg Lyophilized Vial (Check LC-MS Mass Spec on COA)
Full-Length Tβ4: 500 mcg – 1.5 mg SubQ daily · 7-AA TB-500 Fragment: 2.0–2.5 mg SubQ 2x/week
Why this ratio: How to verify what is in your vial: Check the mass spectrometry (LC-MS) molecular weight on your vendor’s Janoshik or MZ Biolabs COA. ~4,963 Da = Full-Length 43-AA Thymosin Beta-4; ~889 Da = 7-AA Ac-LKKTETQ (TB-500 fragment).
Research Protocols
Summaries of published research. For educational purposes only.
| Protocol Name | Source | Dose | Frequency | Duration | Route | Evidence | Link | Save |
|---|---|---|---|---|---|---|---|---|
| Full-Length 43-AA Thymosin Beta-4 Daily Tissue & Anti-Fibrotic Protocol | reported protocol | 500 mcg – 1,500 mcg (0.5–1.5 mg) | Once daily | 4–6 weeks (followed by 2–4 week break) | Subcutaneous injection | clinical trial | — | |
| Synergistic BPC-157 + Full-Length Tβ4 Recovery Stack | reported protocol | 500 mcg BPC-157 + 500 mcg Full-Length Tβ4 | Once daily | 4–8 weeks | Subcutaneous injection | human | — |
Systemic Inflammation, Tissue Repair & Immune Biomarker Panel (Thymosin Beta-4 (Full-Length 43-AA))
Objective inflammatory, hematologic, and trace-mineral markers to quantify connective-tissue recovery, cytokine resolution, and organ safety.
hs-CRP (High-Sensitivity C-Reactive Protein)
Day 0 + Wk 6–8Why track at baseline: Quantifies baseline systemic IL-6/NF-κB inflammatory burden from tendon, joint, gut, or vascular injury.
Week 6–8 check: Target <1.0 mg/L (optimal <0.5 mg/L) by Week 6–8 as tissue inflammation resolves.
ESR (Sedimentation Rate) & Ferritin
Day 0 + Wk 6–8Why track at baseline: Tracks chronic connective-tissue and autoimmune/mucosal inflammatory activity alongside iron stores.
Week 6–8 check: Downward trend in ESR confirming structural resolution rather than temporary analgesic masking.
CBC with Differential (WBC, Neutrophil/Lymphocyte Ratio)
Day 0 + Wk 6–8Why track at baseline: Evaluates innate/adaptive immune balance (especially for Thymosin Alpha-1, Thymosin Beta-4, LL-37 & KPV).
Week 6–8 check: Balanced lymphocyte count and improved Neutrophil-to-Lymphocyte Ratio (NLR 1.2–2.0).
CMP (Liver/Kidney) + Serum Copper & Zinc Ratio
Day 0 + Wk 6–8Why track at baseline: Verifies baseline hepatic/renal function and checks Copper:Zinc balance before GHK-Cu / GLOW / KLOW protocols.
Week 6–8 check: Maintain 1:1 to 1.2:1 Zinc-to-Copper equilibrium and normal transaminases/creatinine.
Community Outcomes
Community Data Coming Soon
Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!
Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.
Important Warnings
- •Always inspect the LC-MS molecular weight on your vendor’s COA to confirm whether the vial contains 43-AA Tβ4 (~4,963 Da) or 7-AA Ac-LKKTETQ (~889 Da)
- •Prohibited at all times in WADA-tested competition under Section S2.2 (Thymosin-β4 and its derivatives e.g. TB-500)
- •Contraindicated in active malignancy due to pro-angiogenic and cell-migration signaling
- •Removed from the FDA 503A Category 2 compounding list; available in the US as an analytical research reference standard
Where to get Thymosin Beta-4 (Full-Length 43-AA), baseline labs & clinician oversight.
Ascension Peptides (US Vials)
MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.
SwissChems & Limitless Biotech
Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).
Superpower Labs & 503A Telehealth
Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.
Peptide Reconstitution & U-100 Syringe Cheat Sheet
Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.
Related Peptides
More recovery peptides
BPC-157
BPC-157 is a synthetic pentadecapeptide derived from a prote...
TB-500 (Thymosin Beta-4)
TB-500 is the synthetic version of Thymosin Beta-4, a natura...
Wolverine Blend (BPC-157 + TB-500)
The Wolverine Blend (BPC-157 + TB-500) is the gold-standard ...
ARA-290 (Cibinetide)
ARA-290 is a non-erythropoietic peptide derived from erythro...
PEG-MGF (Mechano Growth Factor)
MGF is a splice variant of IGF-1 produced locally in muscle ...
Vendor vs vendor: price per mg
Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.
- Ascension vs SwissChems (3 shared compounds)
- Elite vs SwissChems (3 shared compounds)
- Elite vs Ascension (26 shared compounds)
- Protide vs SwissChems (3 shared compounds)
- Protide vs Ascension (6 shared compounds)
- Ameano vs SwissChems (3 shared compounds)
- Ameano vs Ascension (4 shared compounds)
- Swift vs Ascension (23 shared compounds)
- BioLongevity vs Ascension (16 shared compounds)
- Peptyes vs SwissChems (3 shared compounds)
- Peptyes vs Elite (20 shared compounds)
- Peptyes vs Swift (17 shared compounds)
- Peptyes vs Pure (17 shared compounds)
- Peptyes vs Ascension (20 shared compounds)
Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →
Common questions
How many peptides are in the database?
100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.
Where can I compare peptide prices?
Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.